These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 22332446)
1. High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols. Ben-Haroush A; Farhi J; Ben-Aharon I; Sapir O; Pinkas H; Fisch B Isr Med Assoc J; 2011 Dec; 13(12):753-6. PubMed ID: 22332446 [TBL] [Abstract][Full Text] [Related]
2. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI. Mohsen IA; El Din RE Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528 [TBL] [Abstract][Full Text] [Related]
3. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Goswami SK; Das T; Chattopadhyay R; Sawhney V; Kumar J; Chaudhury K; Chakravarty BN; Kabir SN Hum Reprod; 2004 Sep; 19(9):2031-5. PubMed ID: 15217999 [TBL] [Abstract][Full Text] [Related]
4. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization]. Ye H; Huang G; Pei L Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366 [TBL] [Abstract][Full Text] [Related]
5. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer. Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845 [TBL] [Abstract][Full Text] [Related]
6. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156 [TBL] [Abstract][Full Text] [Related]
8. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate. Fatum M; McVeigh E; Child T Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119 [TBL] [Abstract][Full Text] [Related]
9. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer]. Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062 [TBL] [Abstract][Full Text] [Related]
10. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617 [TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142 [TBL] [Abstract][Full Text] [Related]
12. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. Azim AA; Costantini-Ferrando M; Lostritto K; Oktay K J Clin Endocrinol Metab; 2007 Jun; 92(6):2197-200. PubMed ID: 17356042 [TBL] [Abstract][Full Text] [Related]
13. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer]. Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462 [TBL] [Abstract][Full Text] [Related]
14. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. Oktay K; Hourvitz A; Sahin G; Oktem O; Safro B; Cil A; Bang H J Clin Endocrinol Metab; 2006 Oct; 91(10):3885-90. PubMed ID: 16882752 [TBL] [Abstract][Full Text] [Related]
15. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507 [TBL] [Abstract][Full Text] [Related]
16. The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. Ozcan Cenksoy P; Ficicioglu C; Kizilkale O; Suhha Bostanci M; Bakacak M; Yesiladali M; Kaspar C Gynecol Endocrinol; 2014 Jul; 30(7):485-9. PubMed ID: 24592985 [TBL] [Abstract][Full Text] [Related]
17. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479 [TBL] [Abstract][Full Text] [Related]
18. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression. Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Barroso G; Menocal G; Felix H; Rojas-Ruiz JC; Arslan M; Oehninger S Fertil Steril; 2006 Nov; 86(5):1428-31. PubMed ID: 16978619 [TBL] [Abstract][Full Text] [Related]
20. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study. Olgan S; Humaidan P Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]